BioCryst Pharmaceuticals Inc is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. The company's core activities include internal discovery and development of oral small-molecule and injectable protein therapeutics, strategic business development to acquire rare disease assets, and leveraging its commercial infrastructure to support product commercialization. BioCryst aims to optimize costs and allocate resources efficiently by concentrating on rare disease markets to drive sustainable growth.

BioCryst generates revenue primarily through the commercialization of its approved products, including ORLADEYO for hereditary angioedema prophylaxis and RAPIVAB for acute uncomplicated influenza treatment. The company also earns income from licensing agreements, royalty payments, and milestone payments from collaborators such as Torii Pharmaceutical for ORLADEYO in Japan and Shionogi for peramivir in Japan and Taiwan. Revenue is derived from product sales in key markets including the United States, Europe, Japan, and other global territories where its therapies are approved and distributed.

The company operates through the following segments:

• ORLADEYO: This segment focuses on the development and commercialization of berotralstat, an oral, once-daily therapy for the prevention of hereditary angioedema attacks. ORLADEYO is available in capsule form for patients aged 12 years and older and as an oral pellet formulation for pediatric patients aged 2 to <12 years. The product is marketed under the ORLADEYO brand name in the United States and multiple global markets.

• Navenibart: This segment involves the development of STAR-0215, a monoclonal antibody plasma kallikrein inhibitor for hereditary angioedema prophylaxis. Navenibart is currently in Phase 3 clinical development and has received Fast Track and Orphan Drug designations from the FDA and Orphan Medicinal Product Designation from the European Commission. The goal is to deliver a best-in-class injectable therapy with a differentiated every 3- and 6-month administration schedule.

• BCX17725: This segment centers on a potent and selective investigational protein therapeutic KLK5 inhibitor for the treatment of Netherton syndrome. BCX17725 is designed to restore the normal skin barrier by replacing missing functions of the natural KLK5 inhibitor. The candidate is in Phase 1 clinical development in the United States and Australia and has received Fast Track designation from the FDA for Netherton syndrome.

• Avoralstat: This segment advances an investigational plasma kallikrein inhibitor for the treatment of diabetic macular edema via suprachoroidal delivery to the back of the eye. Avoralstat targets the kallikrein-bradykinin pathway to reduce vascular leakage and edema, aiming to lessen treatment burden. Clinical evaluation is ongoing in Australia, with plans to seek a strategic partner for development beyond Phase 1.

• STAR-0310: This segment develops a monoclonal antibody OX40 antagonist incorporating YTE half-life extension technology for atopic dermatitis. STAR-0310 is currently in a Phase 1a trial to assess safety, tolerability, pharmacokinetics, and immunogenicity in healthy subjects. The company plans to seek strategic alternatives for this asset following the acquisition of Astria Therapeutics.

• Peramivir Injection: This segment includes the commercialization of peramivir injection under the brand names RAPIVAB in the United States, Australia, and Canada; RAPIACTA in Japan and Taiwan; and PERAMIFLU in Korea. These products are intravenous neuraminidase inhibitors approved for the treatment of acute uncomplicated influenza.

BioCryst holds a competitive position in the rare disease therapeutics market, particularly in hereditary angioedema, where it faces competition from companies such as Takeda (Takhzyro), Pharming (Haegarda and Cinryze), and CSL Behring (Berinert). Its competitive advantages include a first-in-class oral prophylactic therapy for children aged 2 to <12 years with ORLADEYO pellets, a differentiated dosing schedule for navenibart, and a validated commercial infrastructure that enables efficient product launch and market penetration. The company’s structure-guided drug design capabilities and focus on underexplored biological targets further strengthen its pipeline differentiation.

BioCryst serves patients with rare diseases, including individuals with hereditary angioedema across all age groups, patients with Netherton syndrome, those suffering from diabetic macular edema, and individuals with atopic dermatitis. The company also supplies peramivir injection to government stockpiling programs via contracts with the U. S. Department of Health and Human Services for pandemic preparedness. Specific customer entities include specialty pharmacy providers in the United States, government health agencies such as the U. S. ASPR for RAPIVAB procurement, and international distributors like Neopharmed Gentili for European ORLADEYO commercialization prior to the asset sale.